Genetic Deletion and Pharmacological Inhibition of PI3Kγ Reduces Neutrophilic Airway Inflammation and Lung Damage in Mice with Cystic Fibrosis-Like Lung Disease

Maria Galluzzo, Elisa Ciraolo, Monica Lucattelli, Eriola Hoxha, Martina Ulrich, Carlo Cosimo Campa, Giuseppe Lungarella, Gerd Doring, Zhe Zhou-Suckow, Marcus Mall, Emilio Hirsch, and Virginia De Rose

1Department of Clinical and Biological Sciences, University of Torino, A.O.U. Luigi Gonzaga, Regione Gonzole 10, Orbassano, 10043 Turin, Italy
2Department of Molecular Biotechnology and Health Sciences, Center for Molecular Biotechnology, University of Torino, Via Nizza 52, 10126 Turin, Italy
3Department of Physiopathology, Experimental Medicine, and Public Health, University of Siena, 53100 Siena, Italy
4Department of Neuroscience, University of Turin, 10126 Turin, Italy
5Institute of Medical Microbiology and Hygiene, University of Tübingen, 72074 Tübingen, Germany
6Department of Translational Pulmonology, Translational Lung Research Center Heidelberg (TLRC), German Center for Lung Research (DZL), University of Heidelberg, 69120 Heidelberg, Germany

Correspondence should be addressed to Emilio Hirsch; Emilio.hirsch@unito.it and Virginia De Rose; virginia.drose@unito.it

Received 14 November 2014; Accepted 20 January 2015

Academic Editor: Anshu Agrawal

Copyright © 2015 Maria Galluzzo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Purpose. Neutrophil-dominated airway inflammation is a key feature of progressive lung damage in cystic fibrosis (CF). Thus, reducing airway inflammation is a major goal to prevent lung damage in CF. However, current anti-inflammatory drugs have shown several limits. PI3Kγ plays a pivotal role in leukocyte recruitment and activation; in the present study we determined the effects of genetic deletion and pharmacologic inhibition of PI3Kγ on airway inflammation and structural lung damage in a mouse model of CF lung disease.

Methods. βENaC overexpressing mice (βENaC-Tg) were backcrossed with PI3Kγ-deficient (PI3KγKO) mice. Tissue damage was assessed by histology and morphometry and inflammatory cell number was evaluated in bronchoalveolar lavage fluid (BALF). Furthermore, we assessed the effect of a specific PI3Kγ inhibitor (AS-605240) on inflammatory cell number in BALF. Results. Genetic deletion of PI3Kγ decreased neutrophil numbers in BALF of PI3KγKO/βENaC-Tg mice, and this was associated with reduced emphysematous changes. Treatment with the PI3Kγ inhibitor AS-605240 decreased the number of neutrophils in BALF of βENaC-Tg mice, reproducing the effect observed with genetic deletion of the enzyme. Conclusions. These results demonstrate the biological efficacy of both genetic deletion and pharmacological inhibition of PI3Kγ in reducing chronic neutrophilic inflammation in CF-like lung disease in vivo.

1. Introduction

Cystic fibrosis (CF), the most common genetic disease in Caucasian populations, results from mutations in a single gene encoding for 1480 residues transmembrane glycoprotein, the cystic fibrosis transmembrane conductance regulator (CFTR), that regulates cAMP-mediated chloride conductance at the apical surface of secretory epithelia [1, 2]. Impaired CFTR-mediated secretion of Cl- and bicarbonate results in dehydration and acidification of the airway surface liquid, which in turn causes impaired mucociliary clearance and bacterial killing. These defects trigger a progressive lung disease characterized by airway mucus obstruction, chronic neutrophilic inflammation, bacterial infection, and structural lung damage that remains the major cause of morbidity and mortality in patients with CF [3].
A growing number of *in vitro* and *in vivo* studies support the notion that chronic neutrophilic inflammation with the release of damaging neutrophil products, such as neutrophil elastase, constitutes a key risk factor in early structural lung damage and lung function decline in CF [4–6]. Neutrophilic airway inflammation is augmented after onset of chronic bacterial infection with *Pseudomonas aeruginosa* and other pathogens. In this context, the inflammatory response in the CF lung is nonresolving and self-perpetuating, and a vicious cycle of neutrophilic inflammation, noxious mediator release, and overwhelmed defenses amplifies inflammation, perpetuates infection and contributes to irreversible lung damage and disease progression [7–9]. Therefore, anti-inflammatory therapy, combined with antibiotic therapy, appears crucial to prevent chronic lung damage. However, traditional therapeutic strategies, as well as more recently studied anti-inflammatory drugs, have shown several limitations and limited clinical benefit [8–10]. Clearly, novel approaches have to be undertaken to provide effective anti-inflammatory therapy to CF patients. One possibility is to interfere with leukocyte trafficking into CF airways. Trafficking of leukocytes is controlled by chemotactic factors which bind to heterotrimeric G-protein–coupled receptors (GPCR) and trigger a complex set of signaling pathways inside the cell involving the generation of second messengers like phosphoinositides. Phosphoinositides are substrates of the phosphoinositide 3-kinases (PI3Ks), enzymes that catalyze the phosphorylation of the phosphatidylinositol at the 3rd position of the inositol ring. PI3Ks modulate a wide number of cellular functions such as proliferation and survival, cytoskeletal remodeling, and membrane trafficking and represent important mediators in the signaling cascade leading to the initiation of the inflammatory response [11–14]. PI3Ks can be divided in three classes (I, II, and III) based on their biochemical properties. Leukocytes express all four known isoforms of class I PI3Ks, namely, PI3K , , and [14]; nonetheless PI3K plays a fundamental role in leukocyte migration and function by acting as a chemokine sensor and regulating neutrophil oxidative burst, T cell proliferation, and mast degranulation. We therefore hypothesized that PI3K plays a pivotal role in mediating leukocyte recruitment and activation and may thus represent a potential target for anti-inflammatory treatment to reduce neutrophilic airway inflammation and lung damage in CF. To test this hypothesis, we used transgenic mice with airway-specific overexpression of the epithelial Na+ channel (ENaC) and determined the effects of genetic deletion and pharmacologic inhibition of PI3K [15–17].

2. Materials and Methods

2.1. Mice. PI3K , ENaC-Tg (ENaC-Tg) [15–18] and PI3K-deficient (PI3K, Harlan, Italy) mice on the C57BL/6 background were intercrossed to generate ENaC-Tg/PI3K mice. All experiments were performed in 7- to 8-week-old adult mice. ENaC-Tg, PI3K, PI3K/ ENaC-Tg, and wild-type (PI3K) mice were housed in a pathogen-free animal facility at the Istituto per la Ricerca e la Cura del Cancro, University of Turin, in accordance with the Institutional Animal Welfare Guidelines and Italian legislation. The animal study protocols were reviewed and approved by the Institutional Animal Ethics Committee of the Istituto per la Ricerca e la Cura del Cancro, University of Turin, Turin, Italy, and performed according to the Institutional Animal Welfare Guidelines and Italian legislation.

2.2. Assessment of Inflammatory Cells in Bronchoalveolar Lavage. Inflammatory cell numbers were assessed in the bronchoalveolar fluid (BALF) of PI3K , ENaC-Tg, PI3K, and PI3K/ ENaC-Tg mice. Briefly, mice from each genotype were sacrificed and BALF was then collected by lavaging lungs in situ with 3 × 1-mL volumes of PBS. After centrifugation of the BALFs, cell pellets, in 500 μL of RPMI medium, were deposited onto glass slides using a Cytospin Cytocentrifuge. Slides were then stained using the Diff-Quick system (MICROPTIC S.L., Spain) and a differential cell count was performed as previously described [19]. In addition, BALF inflammatory cells were also analyzed in mice treated with the PI3K inhibitor AS-605240 [5-(quinolin-6-ylmethylidene)-1,3-thiazolidine-2,4-dione] (Sigma, Germany). PI3K, and PI3K/ ENaC-Tg mice were treated once daily for 3 days with the AS-605240 by intraperitoneal injection of 10 mg/kg of the drug or vehicle (0.5% carboxymethyl cellulose, 0.25% Tween) alone.

2.3. Lung Histology and Morphometry. Animals of each group were sacrificed under anaesthesia with pentobarbital (60 mg/Kg) and the lungs fixed intratracheally with buffered formalin (5%) at a constant pressure of 20 cm H₂O. Lung volume (V) was measured by water displacement according to Scherle [20]. Sagittal sections of each pair of lungs were cut and stained with haematoxylin/eosin. The slides were coded to prevent bias. Morphometric evaluations included determination of the average interalveolar distance (mean linear intercept: Lm) [21] and internal surface area (ISA) estimated by the Lm method at postfixation lung volume by the formula 4V/Lm, where V is the postfixation lung volume [22]. For the determination of the Lm for each pair of lungs, 40 histological fields were evaluated both vertically and horizontally. The development of goblet cell metaplasia was evaluated by periodic acid–Schiff reaction (PAS) according to standard histological protocols [23]. The total number of cells, as well as the percentage of PAS-positive cells, was determined. The number of cells in airways that demonstrated PAS staining was determined by examining eight intrapulmonary airways per section and counting at least 3,000 cells/section. Data were reported as the percentage of positive cells per total cells.

2.4. Statistical Analysis. Statistical analyses were performed using one-way analysis of variance. Survival curves were compared using Kaplan-Meier log rank analysis. P < 0.05 was considered statistically significant and “n” represents the number of mice in each experimental group. Data are expressed as mean ± SD.
3. Results

3.1. Genetic Deletion of PI3Kγ Reduces Neutrophilic Airway Inflammation and Mortality in βENaC-Tg Mice. As observed in previous studies, βENaC-Tg (PI3KγWT/βENaC-Tg; Figure 1(a)) mice on the C56BL/6J background exhibited a spontaneous mortality of ~23% [18, 24]. Deletion of PI3Kγ had no effect on survival in wild-type mice; however, in the presence of the βENaC transgene (PI3KγKO/βENaC-Tg), PI3Kγ loss significantly reduced the mortality by ~50%, since at 60 days the survival rate is more than 85% (P < 0.005, Figure 1(a)).

To determine the effect of genetic deletion of PI3Kγ on airway inflammation, we compared inflammatory cell numbers in BAL fluid from surviving PI3KγWT/βENaC-Tg and PI3KγKO/βENaC-Tg mice. As expected, in homozygous PI3KγWT and PI3KγKO control mice, neutrophils were rarely detected in the BALF (Figure 1(b)) as well as in the airways lumen (Figure 1(c)). The number of neutrophils, in BALF and in the airways lumen, was markedly elevated in PI3KγWT/βENaC-Tg mice (Figures 1(b) and 1(c)). On the contrary, the absence of PI3Kγ expression in PI3KγKO/βENaC-Tg mice led to a large reduction of neutrophil recruitment into the lung if compared to PI3KγWT/βENaC-Tg mice (Figure 1(b)). Nonetheless, deletion of PI3Kγ did not affect macrophage and lymphocyte recruitment as no differences were detected between PI3KγKO/βENaC-Tg and PI3KγWT/βENaC-Tg mice in BALF (Figures 1(d) and 1(e)).

3.2. Genetic Deletion of PI3Kγ Reduces Structural Lung Damage in βENaC-Tg Mice. Chronic inflammation, in PI3KγWT/βENaC-Tg mice, triggers emphysema with distal airspace enlargement and alveolar destruction resulting in reduced lung tissue density and increased lung compliance [6, 17, 19]. To assess the protective effects of the genetic deletion of PI3Kγ on emphysema-like changes in PI3KγKO/βENaC- Tg mice, we determined the averaged interalveolar distance (mean linear intercept, Lm) and the internal surface area (ISA) estimated by the Lm method at postfixation lung volume. ISA and Lm were not altered in the lungs of controls PI3KγWT and PI3KγKO mice (Figures 2(a) and 2(b)), and morphological analysis showed a well-fixed normal parenchyma with normal airways (data not shown). As expected from previous studies [6, 17, 19], PI3KγWT/βENaC- Tg mice lungs showed significant emphysematous changes (Figures 2(a)–2(c)) while the genetic deletion of PI3Kγ in PI3KγKO/βENaC-Tg mice resulted in a significant reduction of the degree of emphysema, as assessed by both morphometric analyses (ISA: P < 0.0002 versus PI3KγWT/βENaC- Tg mice; Lm: P < 0.0003 versus PI3KγWT/βENaC-Tg mice; Figures 2(a) and 2(b)) and morphology (Figure 2(c)).

In addition to neutrophilic inflammation, goblet cell metaplasia and mucus obstruction were a common feature of the airways of adult PI3KγWT/βENaC-Tg mice [19]. Since neutrophil products, such as neutrophil elastase, have been implicated in goblet cell metaplasia and mucin hypersecretion in CF [25, 26], we assessed the effects of genetic deletion of PI3Kγ on goblet cell metaplasia. Goblet cells were not observed in PI3KγWT and PI3KγKO mice; in PI3KγKO/βENaC-Tg mice, the goblet cell metaplasia appeared reduced compared to PI3KγWT/βENaC-Tg mice; however, this difference was not statistically significant, based on the variability and the number of mice included in our studies (data not shown).

3.3. Pharmacological Inhibition of PI3Kγ Reduces Neutrophilic Airway Inflammation in βENaC-Tg Mice. Next we tested effects of pharmacological inhibition of PI3Kγ by using the inhibitor AS-605240 on airway inflammation in βENaC-Tg mice. Treatment of βENaC-Tg mice with AS-605240 but not with vehicle alone reduced neutrophil infiltrates in BALF of βENaC-Tg mice (Figure 3(a)). In contrast, as observed in PI3KγKO/βENaC-Tg mice, the PI3Kγ inhibitor had no effect on the recruitment of macrophages or lymphocytes into the lung (Figures 3(b) and 3(c)).

4. Discussion

Progressive lung disease is the major cause of morbidity and mortality in CF and is characterized by chronic airway infection and associated airway inflammation leading to irreversible lung destruction and early death [1–3]. Accumulating evidences suggest that CFTR dysfunction impairs mucociliary clearance and bacterial killing as crucial innate defense mechanisms of the lung leading to chronic bacterial infection and nonresolving inflammation in CF airways [3]. The main feature of airway inflammation in CF is a persistent influx of neutrophils that release a variety of oxidants and granule-associated enzymes, thus contributing to the development of lung injury and to the chronicity of pulmonary infection [7–9]. Repeated episodes of exacerbation of chronic infection and inflammation occur during the natural history of the disease, further increasing the structural damage in the CF lung [27, 28]. Therefore, anti-inflammatory therapy, combined with antibiotic therapy, offers a rational approach to prevent chronic lung damage. However, current anti-inflammatory drugs have shown several limits. The use of oral corticosteroids has been limited by severe adverse effects and studies using inhaled corticosteroids in CF have not been particularly successful [8, 9]. In addition, nonsteroidal anti-inflammatory drugs, such as ibuprofen, although revealing beneficial effects in younger CF patients [29], are difficult to dose and thus are not widely used [30]. Likewise, a phase 3 study of the LTB4 receptor antagonist BIL 284 had been stopped due to adverse effects in the treatment group [31]. An alternative approach to decrease chronic inflammation is to use a more targeted anti-inflammatory therapy directed at reducing neutrophil trafficking in the CF lung. In this context, class I PI3K member, PI3Kγ, has been demonstrated to play a pivotal role in mediating leukocyte recruitment and activation into sites of inflammation [11]. Therefore PI3Kγ may represent an innovative and appropriate target to interfere with the excessive neutrophil-mediated inflammation and damage in CF. Of note, recently developed small-molecule
Figure 1: Continued.
PI3K inhibitors were shown to be effective in suppressing joint inflammation in mouse models of rheumatoid arthritis [32]. In the present study we evaluated the effects of genetic deletion and pharmacologic inhibition of PI3K in the βENaC-Tg mouse as a model of CF lung disease [15, 16, 33]. Such model phenocopies the airway surface dehydratisation and mucociliary dysfunction characteristic of CF airways. βENaC-Tg mice develop spontaneous CF-like lung disease with early onset goblet cell metaplasia and airway mucus obstruction, reduced bacterial clearance, and chronic neutrophilic inflammation triggering emphysema-like structural lung damage [15, 17, 34, 35]. Genetic deletion of PI3Kγ resulted in decreased neutrophil numbers in BALF of PI3KγKO/βENaC-Tg mice, and reduced neutrophilia was associated with reduced emphysematous changes in these mice. Taken together, these data support an important role of PI3Kγ for transmigration of neutrophils from the blood into the airway lumen and a crucial role of neutrophilic airway inflammation in the in vivo pathogenesis of lung damage. Several leukocyte-derived proteases including neutrophil elastase have been shown to cause emphysema in mice [36–38]. Furthermore, previous studies demonstrated that overexpression of several proinflammatory mediators in genetically modified mice induces an imbalance in the pulmonary protease/antiprotease system and emphysema in these mice [39, 40]. Thus, it is likely that neutrophil-dominated chronic pulmonary inflammation and the disruption of protease/antiprotease balance contribute to the development of emphysema in PI3KγWT/βENaC-Tg mice. Neutrophil elastase (NE) is the major product of activated neutrophils and has been implicated in the pathogenesis of key features of CF lung disease, such as chronic airway inflammation, mucus hypersecretion, goblet cell metaplasia, and structural damage [41–47]. We hypothesize that deletion of PI3Kγ decreases lung damage through the reduction of neutrophilic inflammation and neutrophil-associated active elastase. Consistently, a recent study demonstrated that NE activity is increased at the surface of airway neutrophils in PI3KγWT/βENaC-Tg mice and patients with CF [6] and that genetic deletion of NE results in a significant reduction of emphysema-like changes in PI3KγWT/βENaC-Tg mice, suggesting that NE is implicated in emphysema associated with chronic neutrophilic airway inflammation in vivo.

Recently, selective PI3Kγ inhibitors have been developed and investigated in different mouse models of chronic inflammation [48–51]. Therefore, we evaluated the efficacy...
of the PI3K inhibitor AS-605240 on airway inflammation in βENaC-Tg mice; we decided to use AS-605240 for its well characterized in vivo profile of efficacy and selectivity, indicated by the so far largest number of reports of pharmacological PI3K inhibition in mice [48–53]. We showed that treatment with the PI3K inhibitor decreased the number of neutrophils in BALF of βENaC-Tg mice, thus reproducing the effect observed with the genetic deletion of PI3K. Several technical problems limit the assessment of the increased PI3K activity in βENaC mice; however, the findings that PI3K\textsuperscript{WT}/βENaC-Tg inflamed lungs have more leukocytes than PI3K\textsuperscript{KO}/βENaC-Tg controls are an indirect indication of increased PI3K\textsuperscript{γ} activity in these mice. Taken together, our data demonstrate the biological efficacy of both genetic deletion and pharmacological inhibition of PI3K\textsuperscript{γ} in reducing chronic neutrophilic inflammation in CF-like lung disease in vivo.

Whereas blockade of PI3K activity by small-molecule inhibitors may represent a valid approach to modulate excessive leukocyte accumulation in inflamed tissues where...
leukocyte recruitment is correlated with disease progression, on the other hand increased susceptibility to infection might be a potential side effect of the use of these molecules. In this context, a previous study [54] showed that either gene deletion or pharmacologic inhibition of PI3KY in mice infected with S. pneumoniae caused an impaired exudate macrophage recruitment associated with a reduced lung pneumococcal clearance and an impaired resolution/repair process, leading to progressive pneumococcal pneumonia. Thus, whereas pharmacological inhibition of PI3KY, eventually in association with antibacterial treatment, may be a viable strategy to inhibit chronic inflammation and limit lung damage in stable CF lung disease, it might have adverse effects on host defense in acute infections when high bacterial
burden occurs. In view of a clinical application of PI3K inhibitors, target validation will be an important future aspect to discriminate between specific effects of the drug and potential side effects.

5. Conclusions

Neutrophil-dominated airway inflammation has been implicated as a key feature of progressive lung damage in CF. Thus, reducing airway inflammation is a major goal to prevent lung damage and maintain lung function in CF. Current therapeutic strategies that aim to reduce chronic neutrophilic inflammation in the airways of CF patients have been largely unsuccessful. This study shows that genetic deletion and pharmacological inhibition of PI3Kγ decrease neutrophilic airway inflammation and structural lung damage in a mouse model of CF lung disease. These results provide insight into the molecular mechanisms of chronic airway inflammation and suggest a novel treatment strategy to reduce inflammation and lung damage in patients with CF and potentially other neutrophilic airway diseases. Further studies with emerging PI3Kγ inhibitors [49–51] are required to confirm the efficacy of these molecules and exclude their potentially adverse effects on host defense.

Disclosure

Emilio Hirsch and Virginia De Rose are co-senior authors.

Conflict of Interests

Emilio Hirsch has equity ownership in Kither Biotech S.r.l. which is developing products related to the research being reported. Marcus Mall is inventor of a patent filed by the University of North Carolina and related to βENaC transgenic mice. All other authors declare that there is no conflict of interests regarding the publication of this paper.

Authors’ Contribution

Maria Galluzzo and Elisa Ciraolo contributed equally to this work. Gerd Doring is deceased.

Acknowledgments

This work was supported by a research grant from Italian Cystic Fibrosis Research Foundation (Project FFC #20/2009).

References

[1] F. Ratjen and G. Döring, “Cystic fibrosis,” The Lancet, vol. 361, no. 9358, pp. 681–689, 2003.
[2] B. P. O’Sullivan and S. D. Freedman, “Cystic fibrosis,” The Lancet, vol. 373, no. 9678, pp. 1891–1904, 2009.
[3] M. A. Mall and D. Hartl, “CFTR: cystic fibrosis and beyond,” European Respiratory Journal, vol. 44, no. 4, pp. 1042–1054, 2014.
[4] P. D. Sly, C. L. Gangell, L. Chen et al., “Risk factors for bronchiectasis in children with cystic fibrosis,” The New England Journal of Medicine, vol. 368, no. 21, pp. 1963–1970, 2013.
[5] S. D. Sagel, B. D. Wagner, M. M. Anthony, P. Emmett, and E. T. Zemanick, “Sputum biomarkers of inflammation and lung function decline in children with cystic fibrosis,” American Journal of Respiratory and Critical Care Medicine, vol. 186, no. 9, pp. 857–865, 2012.
[6] S. Gehrig, J. Duerr, M. Weitnauer et al., “Lack of neutrophil elastase reduces inflammation, mucus hypersecretion, and emphysema, but not mucus obstruction, in mice with cystic fibrosis-like lung disease,” American Journal of Respiratory and Critical Care Medicine, vol. 189, no. 9, pp. 1082–1092, 2014.
[7] V. de Rose, “Mechanisms and markers of airway inflammation in cystic fibrosis,” European Respiratory Journal, vol. 19, no. 2, pp. 333–340, 2002.
[8] J. F. Chmiel and M. W. Konstan, “Inflammation and anti-inflammatory therapies for cystic fibrosis,” Clinics in Chest Medicine, vol. 28, no. 2, pp. 331–346, 2007.
[9] M. Cohen-Cymberknoh, E. Kerem, T. Ferkol, and A. Elizur, “Airway inflammation in cystic fibrosis: molecular mechanisms and clinical implications,” Thorax, vol. 68, no. 12, pp. 1157–1162, 2013.
[10] W. A. Prescott Jr. and G. E. Johnson, “Anti-inflammatory therapies for cystic fibrosis: past, present, and future,” Pharmacotherapy, vol. 25, no. 4, pp. 555–573, 2005.
[11] E. Hirsch, V. L. Katanova, C. Garlanda et al., “Central role for G protein-coupled phosphoinositide 3-kinase gamma in inflammation,” Science, vol. 287, no. 5455, pp. 1049–1052, 2000.
[12] E. Hirsch, E. Ciraolo, A. Ghigo, and C. Costa, “Taming the PI3K team to hold inflammation and cancer at bay,” Pharmacology and Therapeutics, vol. 118, no. 2, pp. 192–205, 2008.
[13] A. Ghigo, F. Damilano, L. Braccini, and E. Hirsch, “PI3K inhibition in inflammation: toward tailored therapies for specific diseases,” BioEssays, vol. 32, no. 3, pp. 185–196, 2010.
[14] A. Ghigo, F. Morello, A. Perino, and E. Hirsch, “Phosphoinositide 3-kinases in health and disease,” in Phosphoinositides I: Enzymes of Synthesis and Degradation, vol. 58 of Subcellular Biochemistry, pp. 183–213, Springer, Dordrecht, The Netherlands, 2012.
[15] M. Mall, B. R. Grubb, J. R. Harkema, W. K. O’Neal, and R. C. Boucher, “Increased airway epithelial Na⁺ absorption produces cystic fibrosis-like lung disease in mice,” Nature Medicine, vol. 10, no. 5, pp. 487–493, 2004.
[16] Z. Zhou, J. Duerr, B. Johannesson et al., “The ENaC-overexpressing mouse as a model of cystic fibrosis lung disease,” Journal of Cystic Fibrosis, vol. 10, supplement 2, pp. S172–S182, 2011.
[17] M. O. Wielpütz, M. Eichinger, Z. Zhou et al., “In vivo monitoring of cystic fibrosis-like lung disease in mice by volumetric computed tomography,” European Respiratory Journal, vol. 38, no. 5, pp. 1060–1070, 2011.
[18] B. Johannesson, S. Hirtz, J. Schatterny, C. Schultz, and M. A. Mall, “CFTR regulates early pathogenesis of chronic obstructive lung disease in βenac-overexpressing mice,” PLoS ONE, vol. 7, no. 8, Article ID e44059, 2012.
[19] M. A. Mall, J. R. Harkema, J. B. Trojanek et al., “Development of chronic bronchitis and emphysema in beta-epithelial Na⁺ channel-overexpressing mice,” The American Journal of Respiratory and Critical Care Medicine, vol. 177, no. 7, pp. 730–742, 2008.
[20] W. Scherle, "A simple method for volumetry of organs in quantitative stereology," Mikroskopie, vol. 26, no. 1, pp. 57–60, 1970.
[21] W. M. Thurlbeck, "Measurement of pulmonary emphysema.," The American Review of Respiratory Disease, vol. 95, no. 5, pp. 752–764, 1967.
[22] W. M. Thurlbeck, "The internal surface area of nonemphysematous lungs," American Review of Respiratory Disease, vol. 95, no. 5, pp. 765–773, 1967.
[23] L. Atzori, M. Lucattelli, C. J. Scotton et al., "Absence of proteinase-activated receptor-1 signaling in mice confers protection from fMLP-induced goblet cell metaplasia," The American Journal of Respiratory Cell and Molecular Biology, vol. 41, no. 6, pp. 680–687, 2009.
[24] A. Livraghi, B. R. Grubb, E. J. Hudson et al., "Airway and lung pathology due to mucosal surface dehydration in β-epithelial Na+ channel-overexpressing mice: role of TNF-α and IL-4Rα signaling, influence of neonatal development, and limited efficacy of glucocorticoid treatment," Journal of Immunology, vol. 182, no. 7, pp. 4357–4367, 2009.
[25] J. A. Voynow, B. M. Fischer, D. E. Malarkey et al., "Neutrophil elastase induces mucus cell metaplasia in mouse lung," The American Journal of Physiology—Lung Cellular and Molecular Physiology, vol. 287, no. 6, pp. L1293–L1302, 2004.
[26] J. A. Voynow, L. R. Young, Y. Wang, T. Horger, M. C. Rose, and B. M. Fischer, "Neutrophil elastase increases MUC5AC mRNA and protein expression in respiratory epithelial cells," The American Journal of Physiology—Lung Cellular and Molecular Physiology, vol. 276, no. 5, pp. L835–L843, 1999.
[27] C. H. Goss and J. L. Burns, "Exacerbations in cystic fibrosis: epidemiology and pathogenesis," Thorax, vol. 62, no. 4, pp. 360–367, 2007.
[28] M. W. Konstan, W. J. Morgan, S. M. Butler et al., "Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis," Journal of Pediatrics, vol. 151, no. 2, pp. 134.e1–139.e1, 2007.
[29] M. W. Konstan, P. J. Byard, C. L. Hoppel, and P. B. Davis, "Effect of high-dose ibuprofen in patients with cystic fibrosis," New England Journal of Medicine, vol. 332, no. 13, pp. 848–854, 1995.
[30] M. W. Konstan, "Ibuprofen therapy for cystic fibrosis lung disease: revisited," Current Opinion in Pulmonary Medicine, vol. 14, no. 6, pp. 567–573, 2008.
[31] M. W. Konstan, G. Döring, S. L. Heltsh et al., "A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis," Journal of Cystic Fibrosis, vol. 13, no. 2, pp. 148–155, 2014.
[32] M. Camps, T. Ruckle, H. Ji, and V. Ardissone, "Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis," Nature Medicine, vol. 11, pp. 936–943, 2005.
[33] M. A. Mall, S. Y. Graeber, M. Stahl, and Z. Zhou-Suckow, "Early cystic fibrosis lung disease: role of airway surface dehydration and lessons from preventive rehabilitation therapies in mice," International Journal of Biochemistry and Cell Biology, vol. 52, pp. 174–179, 2014.
[34] M. A. Mall, B. Button, B. Johannesson et al., "Airway surface liquid volume regulation determines different airway phenotypes in liddle compared with betaENaC-overexpressing mice," The Journal of Biological Chemistry, vol. 285, no. 35, pp. 26945–26955, 2010.
[35] J. B. Trojanek, A. Cobos-Corra, S. Diemer et al., "Airway mucus obstruction triggers macrophage activation and matrix metalloproteinase 12-dependent emphysema," The American Journal of Respiratory Cell and Molecular Biology, vol. 51, no. 5, pp. 709–720, 2014.
[36] S. D. Shapiro, N. M. Goldstein, A. M. Houghton, D. K. Kobayashi, D. Kelley, and A. Belaaouaj, "Neutrophil elastase contributes to cigarette smoke-induced emphysema in mice," American Journal of Pathology, vol. 163, no. 6, pp. 2329–2335, 2003.
[37] A. Churg and J. L. Wright, "Proteases and emphysema," Current Opinion in Pulmonary Medicine, vol. 11, no. 2, pp. 153–159, 2005.
[38] R. D. Hautamaki, D. K. Kobayashi, R. M. Senior, and S. D. Shapiro, "Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice," Science, vol. 277, no. 5334, pp. 2002–2004, 1997.
[39] M. Fujita, J. M. Shannon, C. G. Irvin et al., "Overexpression of tumor necrosis factor-alpha produces an increase in lung volumes and pulmonary hypertension," The American Journal of Physiology—Lung Cellular and Molecular Physiology, vol. 280, no. 1, pp. L39–L49, 2001.
[40] T. Zheng, Z. Zhu, Z. Wang et al., "Inducible targeting of IL-13 to the adult lung causes matrix metalloproteinase- and cathespindependent emphysema," Journal of Clinical Investigation, vol. 106, no. 9, pp. 1081–1093, 2000.
[41] J. A. Voynow, B. M. Fischer, and S. Zheng, "Proteases and cystic fibrosis," International Journal of Biochemistry and Cell Biology, vol. 40, no. 6–7, pp. 1238–1245, 2008.
[42] C. T. N. Pham, "Neutrophil serine proteases: specific regulators of inflammation," Nature Reviews Immunology, vol. 6, no. 7, pp. 541–550, 2006.
[43] W. L. Lee and G. P. Downey, "Leukocyte elastase: physiological functions and role in acute lung injury," American Journal of Respiratory and Critical Care Medicine, vol. 164, no. 5, pp. 896–904, 2001.
[44] J. V. Fahy and B. F. Dickey, "Airway mucus function and dysfunction," The New England Journal of Medicine, vol. 363, no. 23, pp. 2233–2247, 2010.
[45] R. L. Gibson, J. L. Burns, and B. W. Ramsey, "Pathophysiology and management of pulmonary infections in cystic fibrosis," American Journal of Respiratory and Critical Care Medicine, vol. 168, no. 8, pp. 918–951, 2003.
[46] C. C. Taggart, C. M. Greene, T. P. Carroll, S. J. O'Neill, and N. G. McElvany, "Elastolytic proteases: inflammation resolution and dysregulation in chronic infective lung disease," American Journal of Respiratory and Critical Care Medicine, vol. 171, no. 10, pp. 1070–1076, 2005.
[47] J. D. Venable, M. K. Ameriks, J. M. Blevitt, R. L. Thurmond, and W.-P. Fung-Leung, "Phosphoinositide 3-kinase gamma (PI3Kγ) inhibitors for the treatment of inflammation and autoimmune disease," Recent Patents on Inflammation and Allergy Drug Discovery, vol. 4, no. 1, pp. 1–15, 2010.
[48] J. G. Foster, M. D. Blunt, E. Carter, and S. G. Ward, "Inhibition of PI3K signaling spurs new therapeutic opportunities in inflammatory/autoimmune diseases and hematological malignancies," Pharmacological Reviews, vol. 64, no. 4, pp. 1027–1054, 2012.
[50] B. Markman, J. J. Tao, and M. Scaltriti, “PI3K pathway inhibitors: better not left alone,” *Current Pharmaceutical Design*, vol. 19, no. 5, pp. 895–906, 2013.

[51] T. D. Cushing, D. P. Metz, D. A. Whittington, and L. R. McGee, “PI3Kdelta and PI3Kgamma as targets for autoimmune and inflammatory diseases,” *Journal of Medicinal Chemistry*, vol. 55, no. 20, pp. 8559–8581, 2012.

[52] A. Fougerat, S. Gayral, P. Gourdy et al., “Genetic and pharmacological targeting of phosphoinositide 3-kinase-gamma reduces atherosclerosis and favors plaque stability by modulating inflammatory processes,” *Circulation*, vol. 117, no. 10, pp. 1310–1317, 2008.

[53] A. Ghigo, A. Perino, H. Mehel et al., “Phosphoinositide 3-kinase gamma protects against catecholamine-induced ventricular arrhythmia through protein kinase A-mediated regulation of distinct phosphodiesterases,” *Circulation*, vol. 126, no. 17, pp. 2073–2083, 2012.

[54] U. A. Maus, M. Backi, C. Winter et al., “Importance of phosphoinositide 3-kinase γ in the host defense against pneumococcal infection,” *American Journal of Respiratory and Critical Care Medicine*, vol. 175, no. 9, pp. 958–966, 2007.